Bosutinib: A Novel Src/Abl Kinase Inhibitor for Chronic Myelogenous Leukemia

Lignende værker

• Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia
  af: Rassi, Fuad El, et al.
  Udgivet: (2013)
• Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling
  af: Bieerkehazhi, Shayahati, et al.
  Udgivet: (2016)
• Bosutinib in the management of chronic myelogenous leukemia
  af: Amsberg, Gunhild Keller-von, et al.
  Udgivet: (2013)
• Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
  af: Druker, Brian J., et al.
  Udgivet: (2000)
• Reduction of Raf Kinase Inhibitor Protein Expression by Bcr-Abl Contributes to Chronic Myelogenous Leukemia Proliferation
  af: Takemura, Tomonari, et al.
  Udgivet: (2010)